Navigation Links
Tekturna Infographic Released by d’Oliveira & Associates Imparts Potential Side Effects of Blood Pressure Drug
Date:4/18/2013

(PRWEB) April 18, 2013

Tekturna (aliskiren), produced by Novartis, is a once-daily pill used to treat high blood pressure (hypertension) and is the first “Renin Inhibitor” drug that regulates the renin enzyme in the kidney. This process assists by narrowing the blood vessels and removes water from the bloodstream in order to improve overall circulation (i). In 2011, the FDA determined that aliskiren products had been prescribed over 2.4 million times to over 451,000 patients in the United States (ii). According to the National Institutes of Health, Novartis has marketed aliskiren under the following names: Amturnide, TekAmlo, Tekturna, TekturnaHCT, and Valturna (iii).

According to a press release from Novartis, the company stopped its ALTITUDE medical study in December of 2011 because Tekturna increased the risk of nonfatal stroke, kidney complications, hyperkalemia, and hypotension in patients with Type-2 diabetes. The study was conducted on the part of Novartis in an effort to expand the uses of Tekturna due to the “product profitability in 2011 was negative (iv).” Additional adverse events were recorded by The Institute for Safe Medication Practices in there October of 2012 issue of Quarter Watch which stated that 100 cases of angioedema (swelling) were reported by Tekturna patients in the first quarter of 2012 (v). The same publication also detailed other cases that included one report of death, two reports labeled life threatening, 15 reports of hospitalization, and a final total of 237 Tekturna adverse event reports, “more than any other blood pressure medication (v).”

The infographic issued by d’Oliveira & Associates provides general information on Tekturna as well as lists possible side effects. Side effects allegedly connected to the high blood pressure drug may include: kidney complications, hyperkalemia, angioedema, heart attack, stroke, and/or birth defects. Visit the Tekturna page and view the infographic here: Tekturna Infographic

If you or a loved one has suffered any injuries after taking Tekturna, you may want to file a claim. You should find the best Tekturna lawyer because you may only have one chance at justice. A personal injury lawyer familiar with this blood pressure drug may be able to provide you with important personal and legal advice. d’Oliveira & Associates, P.C., is working with some of the more experienced dangerous drug lawyers who are handling these cases. Please contact the law offices of d’Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

Sources:
(i) http://www.tekturna.com/info/treating-high-blood-pressure.jsp
(ii) http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm
(iii) http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607039.html
(iv) http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml
(v) http://www.ismp.org/NEWSLETTERS/ACUTECARE/showarticle.asp?id=32

Read the full story at http://www.prweb.com/releases/2013/4/prweb10644073.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. St Jude Retreats Releases New Infographic Which Reports Consequences of Drunk Driving
2. d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
3. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
4. IHC Specialty Benefits Releases an Affordable Care Act Infographic to Help Customers Determine Health Insurance Rebates
5. d'Oliveira & Associates Releases Zimmer Knee Infographic Providing Important Safety Information on High-Flex Knees
6. Loyola University New Orleans Presents a History of Nursing in its New Infographic: Nursing Evolution
7. Law Firm Issues Biomet Hip Infographic Warning Consumers About the Dangers of Biomet Hip Implants
8. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
9. d’Oliveira & Associates Releases Mirena IUD Infographic Describing Bayer’s Deceptive Mirena Simple Style Campaign
10. MacGregor & Collins, LLP Releases New California DUI Infographic
11. Get New Patients, INC Releases New Infographic titled 'Are Negative Reviews Killing Your Medical Practice?"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, Dr. ... Cheng, CitiDent offers a complete range of oral health care, including general dentistry, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On ... Rare Diseases, a continuing medical education (CME) event presented by the Association for ... kind—and a first for ACCORD, whose mission is to provide education, tools, and ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: